Aug 17, 2026 7:40 am EDT OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Aug 13, 2026 8:45 am EDT OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma